CLPT (ClearPoint Neuro, Inc.) Net Profit

Corporate emblem and logo of ClearPoint Neuro, Inc. (CLPT)

This price chart for ClearPoint Neuro, Inc. (CLPT) reflects profit dynamics amounting to -0.04. The business relies on developing high-precision neurosurgery systems, utilizing contract manufacturing for components and cloud storage for scaling. High surgeon loyalty to the brand ecosystem allows the company to flexibly manage the cost of consumables, ensuring stable revenue growth.

CLPT: ClearPoint Neuro, Inc. Net Profit 07/04/2022 - 10/29/2026

Financial and market metric breakdowns for clearpointneuro.com (CLPT)

- current quotes and average value forecast:
Market Chart ClearPoint Neuro|CLPT - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization ClearPoint Neuro, Inc.|CLPT - Total Company Value
- book capitalization data:
Net Assets per Single Share ClearPoint Neuro|CLPT - Book Capitalization|Market Capitalization to Book Value clearpointneuro.com|CLPT - Cumulative Company Assets
- debt and liquidity details:
Aggregate Debt to Equity ClearPoint Neuro, Inc.|CLPT - Long-Term Debt to Capital|Current Liabilities to Capital ClearPoint Neuro|CLPT - Company Aggregate Debts|Debt to Book Value Ratio ClearPoint Neuro, Inc.|CLPT - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings ClearPoint Neuro|Quick Liquidity Indicator clearpointneuro.com
- earnings and valuation multiples information:
CLPT - Net Profit
Fundamental valuation:ClearPoint
Product sample of ClearPoint Neuro, Inc.

Conservative capital demands absolute cash flow transparency to confirm business sustainability. This indicator measures the net balance of funds after deducting all operating expenses from revenue according to GAAP standards. In the case of ClearPoint Neuro, Inc. (CLPT), this reflects the monetization efficiency of high-precision neuronavigation systems. The stability of this process determines the asset's market value. By analyzing the company's profit metrics, an investor identifies the actual solvency of this niche leader.

Key competitors

BSX - Net Financial Result|EW (Edwards Lifesciences) - Net Profit|Net Profit resmed.com|Company Net Income Insulet (PODD)|Company Net Income ZBH (Zimmer Biomet Holdings)|Net Profit COO (CooperVision)|Net Financial Result Align Corp (ALGN)|GMED: Net Income|Profit After Tax TMDX|ATEC: Net Profit|Company Net Income CryoLife (AORT)|ENOV (DJO Global) - Net Profit|Company Profit IART (Integra LifeSciences Inc.)|Net Income ESTA (Establishment Labs)|BBNX (betabionics.com) - Final Profit|Company Net Income IRADIMED IRMD|EMBC - Net Income|Tandem Diabetes - Net Profit|Company Net Income Axogen Surgical|SIBN: Net Profit|Company Profit OFIX|BVS (Bioventus) - Net Profit|OrthoPediatrics Inc. (KIDS) - Net Financial Result|Net Profit TMCI|Net Income Strata Medical SRTA|Net Profit CARL (Carlsmed Inc)|Net Profit rxsight.com RXST|STXS - Company Net Income|STIM: Company Net Income|SGHT (Sight Sciences, Inc) - Net Income|Orchestra BioMed Inc. - Final Profit|ANIK (Anika Therapeutics Inc.) - Net Profit|Company Net Income inspiremd.com NSPR|Company Net Income Jin Medical International (ZJYL)|vivani.com (VANI) - Annual Net Income|Xtant Medical - Net Income|Net Profit NeuroOne Medical Technologies Corp. NMTC|Modular Med - Net Profit|Net Financial Result myomo.com MYO|Envoy Medical (COCH) - Company Net Income|Profit After Tax VVOS (Vivos Therapeutics Inc.)|Company Net Income enVVeno|Net Income SINTX Technologies (SINT)|Net Profit TNON|LFWD - Company Net Income|Company Net Income Autonomix Medical AMIX|IVF: Company Profit|BBLG: Net Income|Axonics, Inc - Profit After Payment of Taxes|BIOL: Net Profit|Net Income Dynatronics|Company Net Income Paragon 28 Inc.|Company Net Income INVO